PharmaJet said today that a trivalent and quadrivalent influenza vaccine is available with its Stratis needle-free injector for this year’s flu season.
PharmaJet’s device is designed to administer medication intramuscularly or subcutaneously, without the use of needles. The Chicago-based company touts the technology as a way to prevent cross-contamination between needles and enhance patient compliance.
“The addition of a quadrivalent influenza vaccine gives healthcare providers a wider choice of vaccines that they can deliver without a needle,” PharmaJet chairman & CEO Ron Lowy said in prepared remarks. “PharmaJet offers the only needle-free delivery system approved by the FDA for administration of inactivated influenza vaccines. Expanding the vaccine selection that can be used with our device is another significant step toward improving public health through expanded immunization coverage, as well as improved safety of caregivers.”
In October last year, the company inked a collaborative deal with Vaccibody to provide needle-free injection tech for the development of a human papillomavirus vaccine.
HPV is the cause of virtually all cervical cancer, according to the National Cancer Institute, and just 2 types of HPV, 16 and 18, are responsible for about 70% of all cases.
In August last year, PharmaJet landed a multi-year partnership with the World Health Organization as part of the group’s effort to eradicate polio using the company’s needle-free tech.
